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Abstract
p53 is a tumor suppressor gene that is frequently mutated in multiple cancer tissues. Activated p53 protein regulates
its downstream genes and subsequently inhibits malignant transformation by inducing cell cycle arrest, apoptosis,
DNA repair, and senescence. However, genes involved in the p53-mediated senescence pathway are not yet fully
elucidated. Through the screening of two genome-wide expression profile data sets, one for cells in which exogenous
p53 was introduced and the other for senescent fibroblasts, we have identified chloride channel accessory 2 (CLCA2)
as a p53-inducible senescence-associated gene. CLCA2 was remarkably induced by replicative senescence as well
as oxidative stress in a p53-dependent manner. We also found that ectopically expressed CLCA2 induced cellular
senescence, and the down-regulation of CLCA2 by small interfering RNA caused inhibition of oxidative stress–induced
senescence. Interestingly, the reduced expression of CLCA2 was frequently observed in various kinds of cancers
including prostate cancer, whereas its expression was not affected in precancerous prostatic intraepithelial
neoplasia. Thus, our findings suggest a crucial role of p53/CLCA2–mediated senescence induction as a barrier for
malignant transformation.
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Introduction
In nearly half of all human cancers, the p53 gene is mutated or deleted
[1]. The p53 protein is induced and activated in the nucleus by a va-
riety of genotoxic stress such as DNA damage, hypoxia, and oxidative
stress [2]. Activated p53 functions as a transcriptional factor, inhibits
cell growth, and suppresses tumor formation by regulating many
genes involved in cell cycle, apoptosis, and cellular senescence [3,4].
Although nearly a hundred p53-inducible genes have been identified
so far [5,6], our recent microarray analysis revealed that there are still
more than 50 p53-inducible genes that have not been well character-
ized yet [7]. To provide the detailed critical biologic functions of p53,
we have previously identified a number of p53 target genes, such as
p53R2, p53AIP1, p53RDL1, and PADI4 [4,8–13].
Senescence is mainly regulated through two major pathways in-
volving p16Ink4a/Rb and p14ARF/p53 [14,15]. Expression of p16Ink4a
markedly increases with aging in mouse and human tissues [16,17].
In addition, p16Ink4a expression was shown to increase in senescent
fibroblasts [18] as well as in response to oxidative stress or DNA
damage [19,20]. p16INK4A functions as a CDK4/CDK6 inhibitor and
subsequently leads to a G1 arrest through the regulation of the pRB-
E2F pathway [21,22].
Conversely, p14ARF controls the level of p53 by inhibiting the
p53-specific ubiquitin ligase MDM2 [21,22]. The role of p53 in
cellular senescence was clearly demonstrated by the fact that p53-
deficient fibroblasts showed resistance to senescence [23]. In addition,
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reactivation of p53 in murine liver carcinoma cells induced tumor re-
gression through the induction of cellular senescence [24], and mice
expressing active mutant p53 displayed an early onset of aging pheno-
types [25]. Hence, it is obvious that activated p53 prevents malignant
transformation of damaged cells by inducing senescence [26]. Because
cellular senescence was observed in precancerous tissues [27,28], senes-
cence is likely to function as a barrier for malignant transformation in
the carcinogenesis process [29].
Among a number of transcriptional targets of p53, p21WAF1 was
shown to play a principle role in both p53-dependent and independent
senescence pathways [30]. p21WAF1 inhibits cell cycle progression
through interaction with the cyclin-CDK complex. However, because
p21WAF1-null fibroblast presents senescent phenotype [31], it is con-
sidered that another p53 target gene(s) may play a pivotal role in
p53-dependent senescence induction. In this study, to identify a novel
p53 target gene(s) that is essential for p53-dependent senescence induc-
tion, we examined the data sets of two genome-wide expression profile
analyses. One data set was obtained using cells in which wild-type p53
was exogenously introduced, and the other was obtained using normal
human dermal fibroblast (NHDF) cells at several time points from low
to high passage (senescent state). Through this screening and sub-
sequent biologic analysis, here we demonstrate a possible role of
CLCA2 as a p53-inducible senescence mediator. We also examined
the expression of CLCA2 in various cancer tissues. CLCA2 was reported
as a p53 target gene that regulates p53-induced apoptotic pathway [32].
In addition, CLCA2 was shown to be downregulated or mutated in
breast cancer tissues [33,34]. Recently, Rovillain et al. [35] reported
that CLCA2 was strongly induced during senescence. Our findings
would further support the crucial role of CLCA2 in the regulation of
the senescence pathway as well as human carcinogenesis.
Materials and Methods
Complementary DNA Microarray
Complementary DNA (cDNA) microarray analysis was carried
out as previously described [36]. For the senescence microarray, the
total RNA of each sample was isolated and amplified using RNeasy
spin column kits (Qiagen, Valencia, CA) and T7-Transcription kit
(Epicentre Technologies, Madison, MI). For the p53 microarray,
poly(A)+ RNAs were isolated from U373MG cells using a standard
protocol. Each RNA sample was labeled and hybridized to a micro-
array consisting of 36,864 cDNA fragments (http://www.ncbi.nlm.
nih.gov/geo/index.cgi, Accession No. GSE14953).
Plasmid Construction
The entire coding sequence of CLCA2 cDNA was amplified by
polymerase chain reaction (PCR) using KOD-Plus DNA polymerase
(Toyobo, Osaka, Japan) and inserted into pCAGGS vector, which
carries a gene conferring neomycin resistance. A Flag epitope tag was
placed at the C-terminus of the CLCA2 expression vector. Constructs
were confirmed by sequencing.
Cell Culture and Transfections
Each cell line was purchased from American Type Culture Col-
lection, Lonza Biologics, Inc, or Japanese Collection of Research
Bioresources. p53-deficient mice were obtained from RIKEN
(http://www.cdb.riken.go.jp/arg/, Accession No. CDB0001K) [37].
We prepared mouse embryonic fibroblasts (MEFs) from embryonic
day 13.5 embryos by standard protocols and maintained them in
Dulbecco modified Eagle medium containing 10% fetal bovine serum.
Replication-deficient recombinant adenovirus encoding p53 (Ad-p53)
or LacZ (Ad-LacZ) was generated and purified, as previously described
[8]. U373MG or H1299 cells were infected with viral solutions at an
indicated multiplicity of infection (MOI) and incubated at 37°C until the
time of harvest. Cells were transfected with plasmids using FuGENE6
(Roche, Basel, Switzerland). Small interfering RNA (siRNA) oligonu-
cleotides, commercially synthesized by Sigma Genosis (The Woodlands,
TX), were transfected with LipofectAMINE 2000 reagent (Life Tech-
nologies, Grand Island, NY) for 4 hours. Sequences of oligonucleotides
are shown in Table W3. For treatment with genotoxic stress, cells were
continuously incubated with hydrogen peroxide (H2O2) or adriamycin
for 2 hours or irradiated by γ-ray or ultraviolet as indicated in the re-
spective figure legends. 5-Aza-2′-deoxycytidine (5-Aza) and trichostatin A
(TSA) were purchased from Sigma.
Quantitative Real-time PCR and Northern Blot Analysis
Isolation of total RNA from cultured cells was performed using
RNeasy spin column kits (Qiagen) according to the manufacturer’s
instructions. Prostate and colorectal cancer tissues were prepared as
previously described [38], and the total RNA of each sample was iso-
lated and amplified. cDNAs were synthesized with the SuperScript
Preamplification System (Invitrogen). Quantitative real-time PCR was
conducted using the SYBR Green I Master or ProbeMaster on a Light-
Cycler 480 (Roche) according to the manufacturer’s recommendations.
β2-Microglobulin or β-actin was used for normalization of expression
levels. For the Northern blot analysis, a 2-μg aliquot of each poly(A)+
RNA was separated on a 1% agarose gel and transferred to nylon mem-
brane by standard procedures. Hybridization with a random-primed
32P-labeled CLCA2 cDNA probe was carried out according to the
manufacturer’s instructions. The primer and probe sequences are indi-
cated in Table W3.
Gene Reporter Assay
DNA fragments, including potential p53-binding sites of mouse
Clca5, were amplified and subcloned into pGL3-promoter vector
(Promega, Madison, WI). To make a series of mutant vectors, a point
mutation “T” was inserted into the site of the 4th, the 7th, the 14th,
and the 17th nucleotides of the consensus p53-BS using inverse PCR
methods. Reporter assay was performed using the Dual Luciferase
Assay System (Promega) as described previously [8].
Antibodies
Rabbits were immunized with the recombinant proteins correspond-
ing to the extracellular domain (amino acids 253-899) of CLCA2.
Anti-Flag monoclonal (clone M2) and polyclonal (F7425) antibodies,
as well as anti–β-actin monoclonal antibody (clone AC15) were pur-
chased from Sigma. Mouse monoclonal anti-p53 (clone DO-1)
and anti-p21WAF1 (clone EA10) antibodies were purchased from
Calbiochem (San Diego, CA). Anti-HA monoclonal antibody (F-7)
was purchased from Santa Cruz Biotechnology, Santa Cruz, CA.
Western Blot Analysis
To prepare whole-cell lysates, cells were collected and lysed in
chilled RIPA buffer (50 mM Tris-HCl at pH 8.0, 150 mM sodium
chloride, 0.1% SDS, 0.5% DOC, 1% NP-40, and 1 mM phenyl
methylsulfonyl fluoride) for 30 minutes on ice and centrifuged at
16,000g for 15 minutes. To concentrate the media, they were mixed
with an equal volume of acetone and kept at −80°C for 1 hour. The
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mixture was then centrifuged at 16,000g for 15 minutes, and the
resulting protein pellets were dissolved in SDS sample buffer. Samples
were subjected to SDS-PAGE and immunoblot analysis by a standard
procedure. Silver staining was carried out using SilverQuest Staining
Kit (Invitrogen) according to the manufacturer’s instructions.
Immunocytochemistry
Adherent cells were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS) and permeabilized with 0.2% Triton X-100 in
PBS for 5 minutes at room temperature. The cells were then covered
with blocking solution (3% bovine serum albumin/PBS containing
0.2% Triton X-100) for 30 minutes at room temperature and incu-
bated with rabbit anti-Flag antibody and mouse anti-HA antibody in
blocking solution for 60 minutes at room temperature. Primary anti-
bodies were stained with Alexa Fluor 488 antirabbit immunoglobulin
G and Alexa Fluor 594 antimouse immunoglobulin G for 1 hour at
room temperature and stained with 4′,6-diamidino-2-phenylindole,
dihydrochloride (DAPI). For cell surface staining, cells were labeled under
nonpermeabilized conditions using the buffer without Triton X-100.
Cell Proliferation and Cell Death Assay
Colony formation assays were carried out in six-well culture plates.
Cells transfected with pCAGGS/CLCA2 or control plasmid were cul-
tured in the presence of geneticin (Invitrogen) for 2 weeks. As a control
plasmid, the entire coding sequence of CLCA2 cDNAwas inserted into
the vector in the opposite direction. Colonies were stained with crystal
violet (Sigma) and scored using Image J software. Soft agar assay was
carried out as previously described [8]. For the cell death assay,
U373MG cells were infected with either Ad-p53 or Ad-LacZ at 6 hours
after transfection of siRNA oligonucleotide. Apoptotic cells were quanti-
fied by FACS analysis as previously described [3]. Cell growth was deter-
mined by MTT assay using Cell Counting Kit-8 (Dojindo, Kumamoto,
Japan) or by BrdU assay using Cell Proliferation ELISA BrdU (Roche).
Senescence-Associated β-Gal Staining
Senescence-associated (SA)–β-gal activity was detected as previously
described [39].
Results
CLCA2 Expression Is Increased during Replicative Senescence
To investigate the genes involved in the process of cellular senescence,
we compared the mRNA expression profiles of early- and late-passage
(senescent) fibroblasts. Newly purchased NHDF cells were serially cul-
tured under the conditions recommended by the distributors. Culture
medium was changed every 3 days. When the cells reached 80% to 90%
confluence, they were detached and plated at a density of 5 × 105 cell
per 10-cm dish (approximately 30% confluence). Cell proliferation ratio
of senescent fibroblast cells declined, and the cells became positive for
SA-β-gal staining, which is a known senescence marker (Figure W1A).
After passaging NHDF cells more than 30 times, they reached the
senescence stage and almost stopped to grow. We conducted a cDNA
microarray analysis using mRNAs from NHDF cells at the 3rd, 7th,
13th, 19th, and 26th passage levels. Through this analysis, we identified
85 genes that were increased by more than 10-fold in senescent fibro-
blast after the 26th passage (Table W1).
To identify novel p53 target genes, we had previously performed
another mRNA expression profile analysis using U373MG p53-
mutant glioblastoma cells in which wild-type p53 (Ad-p53) or LacZ
(Ad-LacZ) were infected using an adenovirus system [7]. The com-
parison of these two data sets revealed six possible candidates that were
increased by more than 10-fold in both data sets (Table W1). After
performing semiquantitative reverse transcription (RT)–PCR for these
six genes, we selected CLCA2 for further analysis because CLCA2 was
remarkably increased during the cellular senescence process as well as by
the ectopic induction of wild-type p53 (Figures 1A and W1, B and C).
We also confirmed the p53-mediated CLCA2 induction by quantita-
tive RT-PCR, Northern, and Western blot analyses (Figures 1, B and
C , and W2A). The specificity of this antibody was verified by siRNA
knockdown (Figure W2, A and B).
To investigate whether CLCA2 is involved in stress-induced pathway,
we analyzed the expression of CLCA2 during oxidative stress–induced
cellular senescence. We treated IMR-90 normal human diploid fibro-
blast cells with hydrogen peroxide (H2O2) and examined the expression
of CLCA2 by quantitative real-time PCR analysis (Figure 1D). Interest-
ingly, p21WAF1 and p16INK4A expression was increased as early as 1 or
2 days after H2O2 treatment, but the highest level of CLCA2 expression
was observed at 8 days in H2O2-treated senescent fibroblasts. These data
suggest that CLCA2 is likely to play some role in the later stages of DNA
damage response.
Clca5 (Mouse Homologue of Human CLCA2)
Is a Target of p53
Because Clca5 (mouse homologue of human CLCA2) was previ-
ously shown to be induced by genotoxic stress and suppress cell
growth [40,41], we investigated whether Clca5 is associated with
the p53-induced senescence induction. When MEFs derived from
p53+/+ or p53−/− embryos were treated with oxidative stress, we
found decreased staining of SA-β-gal in p53−/− MEF (Figure 2A).
We also found that Clca5 expression was induced by oxidative stress
in p53+/+ MEF but not in p53−/− MEF (Figure 2B). We then sur-
veyed the genomic sequence of the Clca5 gene and found three
putative p53-binding sequences (p53BS 1-3) in the promoter or
intron 1 region (Figure 2C ). We subcloned a DNA fragment of
1301 base pairs, which included the three putative p53-binding
sequences into pGL3 promoter vector (pGL3/p53BR; Promega). We
found that cotransfection of pGL3/p53BR with wild-type p53 expres-
sion plasmid enhanced the luciferase activity by more than four-fold,
whereas the base substitutions within BS1 completely diminished the
luciferase activity (Figure 2D). Interestingly, DNA sequence of p53BS1
was highly conserved between mouse Clca5 and human ClCA2
(Figure W3, A-C). These findings indicated that Clca5/CLCA2 could
be involved in the p53-induced senescence pathway.
CLCA2 Contributes to Oxidative Stress–Induced Senescence
To clarify the role of CLCA2 in genotoxic stress–induced senescence
pathway, we analyzed the expression of CLCA2 in H2O2-treated IMR-
90 cells that were transfected with siRNA against p53 (sip53) or
CLCA2 (siCLCA2-1 or siCLCA2-2). The result of quantitative real-
time PCR analysis showed the drastic suppression of CLCA2 expres-
sion by p53 knockdown to the same extent as siCLCA2 treatment
(Figure 3A). Moreover, inhibition of CLCA2 or p53 expression signif-
icantly suppressed H2O2-induced cellular senescence (Figure 3B). We
also examined whether ectopic expression of CLCA2 could induce
cellular senescence. MCF7 cells were stained with SA-β-gal 3 days after
introduction of CLCA2-expression plasmid. As a result, we found an
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increase in positive staining for SA-β-gal in cells expressing CLCA2
compared with Mock-transfected cells (Figure 3, C and D). Taken
together, our findings clearly indicated that p53-CLCA2 pathway
contributes to genotoxic stress–induced senescence.
Down-regulation of CLCA2 in Prostate and Colorectal Cancer
Because CLCA2 was shown to be a potential breast tumor sup-
pressor [34], we examined the expression of CLCA2 in various cancers
using gene expression database that consists of more than 1000 cancer
tissues [36,38,42–44]. The expression of CLCA2 was remarkably
decreased in breast, bladder, esophageal, lung, and prostate cancer
tissues (Table 1). We performed quantitative real-time PCR analyses
and found that CLCA2 mRNA was frequently decreased in prostate
and colorectal cancers (<20% of control in 9 of 10 prostate cancer
tissues and in 10 of 17 colorectal cancer tissues; Figures 4A and
W4A). Cellular senescence was shown to be observed in precancerous
tissues and is likely to function as a barrier for malignant transformation
[45]. Therefore, we investigated the expression of CLCA2 in premalig-
nant tissues of the prostate (prostatic intraepithelial neoplasia [PIN]).
As a result, the expression of CLCA2 in PIN is comparable with that
in their corresponding normal prostate tissues but significantly higher
than that in cancer tissues (Figure 4B).
Because expression of CLCA2 is regulated by p53, inactivation of
p53 is likely to cause the decrease of CLCA2 expression in cancer cells.
Therefore, we examined the CLCA2 expression and the p53 gene
mutation in five prostate cancer cell lines as well as one normal prostate
epithelial cell line. As a result, the expression of CLCA2 was down-
regulated in cancer cell lines compared with that of normal prostate
epithelial cell line (P < .01), but we found no significant difference
in CLCA2 expression between wild-type and mutant p53 cell lines
(Figure 4C ; P = .86). These data suggested that there may be another
mechanism that suppresses CLCA2 expression in cancer cells other than
p53 mutation. Because epigenetic change is one of the major causes of
gene silencing in cancer tissues, we treated three prostate cancer cell
lines with TSA (inhibitor of histone deacetylation) and/or 5-Aza (inhib-
itor of DNA methylation). We found that, after treatment, the CLCA2
expression was partially restored in all three cell lines (Figure 4D), sug-
gesting the possible role of epigenetic alteration in CLCA2 inactivation.
Similarly, 5-Aza treatment increased CLCA2 expression in two colorec-
tal cancer cell lines among seven examined (FigureW4B). Nevertheless,
we found that HCT116 p53−/− cells exhibited lower CLCA2 expression
Figure 1. CLCA2 expression is increased during replicative senescence. (A) Quantitative real-time PCR analysis of CLCA2mRNA in NHDF
cells at indicated passage levels. β2-Microglobulinwas used for the normalization of expression levels. (B) Northern blot and quantitative
real-time PCR analysis of CLCA2 transcript in U373MG cells at indicated times after infection with Ad-p53 or Ad-LacZ at 8 MOIs. β -Actin
was used for the normalization of expression levels. p21WAF1 served as a positive control. (C) Western blot analysis of CLCA2 protein
in U373MG cells at indicated times after infection with Ad-p53 or Ad-LacZ at 40 MOIs. β-Actin was used for the normalization of ex-
pression levels. p53 and p21WAF1 served as a positive control. (D) Quantitative real-time PCR analysis of CLCA2, p21WAF1, and p16Ink4a
mRNA in IMR-90 cells at the indicated days after treatment with 400 μM of H2O2. β2-Microglobulin was used for the normalization of
expression levels.
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than HCT116 p53+/+ cells (Figure W4C). In addition, cells carrying
wild-type p53 exhibited relatively higher CLCA2 expression than cells
with p53 mutation, although the difference was not statistically sig-
nificant (P = .47; Figure W4D and Table W2). Because p53 was fre-
quently inactivated by various mechanisms in cancer tissues, both
epigenetic alteration and p53 inactivation would play crucial roles
in the deregulation of CLCA2 expression in prostate and colorectal
cancer tissues.
Discussion
Here we show that CLCA2 expression is remarkably increased during
cellular senescence. Ectopic expression of CLCA2 induced senescence
in cells, and knockdown of CLCA2 as well as p53 inhibited genotoxic
stress–induced cellular senescence. These findings revealed that CLCA2
is a mediator of p53-induced senescence.
We have previously demonstrated the distinct mechanisms by
which p53 determined cell fate through the induction of different sets
of its target genes. At an early time point after repairable DNA dam-
age, p53 induces p21WAF1 and p53R2, which cooperatively modulate
cell survival through the induction of cell cycle arrest and subsequent
repair of damaged DNA [4]. However, when DNA damage is too
severe to be repaired, specifically activated p53 induces genes such
as p53AIP1, a crucial mediator of apoptotic pathway, to eliminate
the damaged cells [8]. Because senescence is also an irreversible pro-
cess like apoptosis, our finding suggested that p53 regulates cell fate
by inducing senescence associate gene(s) when cells are severely dam-
aged. Actually, CLCA2 expression was peaked at a later time point
during replicative senescence compared with p16Ink4a and p21WAF1,
suggesting the activation of CLCA2 in the aging tissues. Because most
prostate cancer affects elderly men, decreased expression of CLCA2
due to epigenetic alteration or p53 inactivation would play an impor-
tant role in prostate carcinogenesis.
Walia et al. reported that CLCA2 regulates intracellular pH.
Under physiological conditions, the ion channels maintain the body
pH within a range of 7.35 to 7.45. However, the pH of tumor cells
was found to be neutral or alkaline [46]. Higher pH was associated
with the apoptosis resistance and the invasive property of tumor cells,
and inhibition of the Na(+)/H(+) exchanger isoform 1 (NHE1) in-
duced apoptosis in cancer cells [47]. Conversely, aging caused the
change of the composition and function of cell membranes and sub-
sequently decreased the pH [48]. Degenerative neural diseases such
as Parkinson disease and Alzheimer disease indicate a decreased pH
in cells and tissues [49]. Thus, intracellular pH is strongly associated
with oncogenic and senescence phenotype. Taken together, CLCA2
Figure 2. Clca5 (mouse homologue of human CLCA2) is a target of p53. (A, B) p53+/+ and p53−/−MEFs were treated with 100 μM (A) or
150 μM (B) of H2O2. (A) At 6 days after treatment, the cells were subjected to SA-β-gal staining. (B) Quantitative real-time PCR analysis of
Clca5mRNA at indicated days after treatment. β -Actin was used for the normalization of expression levels. (C) Genomic structure of the
mouse Clca5 gene. Gray boxes indicate the locations and relative sizes of the two exons. Arrows indicate the locations of potential p53-
binding sites (p53BS1-3) in a p53-binding region (p53BR). Identical nucleotides to the consensus sequence are written in capital letters.
The underlined nucleotides were substituted for thymine to examine the specificity of each p53-binding site. (D) Results of luciferase
assay of p53BR with or without substitutions at either of the p53BS fragments are shown. Luciferase activity is indicated relative to the
activity of mock vector with SDs (n = 2).
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could function as a barrier for malignant transformation by inducing
cellular senescence and tumor regression through the regulation of
intracellular pH.
N-terminal CLCA2 was shown to be cleaved and secreted into the
culture medium [50]. Although several studies indicated the growth
suppressive effect of membrane-localized CLCA2, the role of soluble
CLCA2 was not well characterized. The physiological significance
of processing at its extracellular domain varies among substrates
proteins. Tumor necrosis factor α is cleaved by TACE and exhib-
its strong systemic effects [51]. In contrast, soluble MICA blocks
natural killer cell activity [52], whereas membrane-bound MICA
stimulates immune response mediated by natural killer cell [53].
E-cadherin is cleaved by metalloproteinase and a residual membrane-
tethered product is degraded by intracellular proteolytic pathway
[54]. Because senescent human fibroblasts were shown to stimulate
proliferation of epithelial cells in vitro and in vivo [55], soluble CLCA2
secreted by the senescence-activated fibroblasts might exhibit growth-
promoting activity in contrast to the membrane-localized CLCA2.
We would like to analyze the role of membrane-localized and soluble
CLCA2 on the regulation of cellular senescence pathway in the fu-
ture study. Many organ-specific serum biomarkers for aging such
as N-telopeptide of type I collagen and MT1-MMP for bone re-
sorption [56], CD4/CD8 ratio for immune system, albumin, and
Figure 3. CLCA2 is a key mediator of oxidative stress–induced senescence. (A, B) IMR-90 cells were transfected with siRNA oligo-
nucleotides designed to suppress the expression of CLCA2 or p53 at 7 hours before treatment with 400 μM of H2O2. siEGFP was used
as a control. At 8 days after treatment, the cells were subjected to quantitative real-time PCR analysis of CLCA2 mRNA (A) and SA-β-gal
staining (B). β2-Microglobulin was used for the normalization of expression levels. The proportion of cells positive for SA-β-gal staining is
indicated (B, upper panels). The representative images of cells are shown (B, lower panels). Asterisks indicate P value obtained by
Student’s t test: *P < .05 and **P < .01. (C, D) MCF7 cells were transfected with CLCA2 expression plasmid. (C) After 3 days, the cells
were subjected to SA-β-gal staining. (D) The proportion of cells positive for SA-β-gal staining is indicated. Asterisk indicates P value
obtained by Student’s t test: **P < .01.
Table 1. Decreased Expression of CLCA2 in Cancer Tissues Examined by cDNAMicroarray Analyses.
Cancer Tissues Suppression of CLCA2
(<1/3), n (%)
Total Samples (n) References
Lung cancer (SCLC) 7 (100) 7 Taniwaki et al. [36]
Prostate cancer 21 (81) 26 Ashida et al. [38]
Esophageal cancer 10 (53) 19 Yamabuki et al. [42]
Breast cancer 30 (46) 66 Nishidate et al. [44]
Bladder cancer 9 (28) 32 Takata et al. [43]
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growth hormone for nutrition [57] are clinically valuable [58]. Telo-
mere length is a good marker for biologic aging [59], but serum
biomarkers of human aging have not yet been clinically validated.
Because CLCA2 was increased in response to genotoxic stress as well
as replicative senescence, serum CLCA2 would be a good biomarker
for aging. Although we have not yet been able to establish an ELISA
test to detect soluble CLCA2 owing to the high background of
antibody, we would like to investigate the role of soluble CLCA2
as a senescence biomarker in the future.
Although further functional analyses, especially for the role of the
cleaved N-terminal fragment, are essential to fully elucidate the role
of CLCA2 in senescence and carcinogenesis, we believe that our find-
ings may lead to the development of a novel cancer therapy by reac-
tivating CLCA2 signaling.
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was used for the normalization of expression levels. Asterisks indicate P value obtained by Student’s t test: *P< .05, **P< .01, and N.S.
(not statistically significant).
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Figure W1. Replicative senescence in late-passage fibroblast. (A)
After 30 times of passage, the cells were subjected to SA-β-gal
staining. (B) RT-PCR analysis of six candidate mRNAs in U373MG
cells at indicated times after infection with Ad-p53 or Ad-LacZ. β2-
Microglobulin was used for the normalization of expression levels.
p21WAF1 served as a positive control. (C) RT-PCR analysis of
C6orf138 and CLCA2 mRNAs in NHDF cells at indicated passage
levels. β2-Microglobulin was used for the normalization of expres-
sion levels. p21WAF1 served as a positive control.
Table W1. List of 85 Senescence-Associated Genes.
Gene P26/P3 p53 Induction
MAST4 >50 ++
RGS4 >50
PPP4R4 >50
ZNF367 >50
SORT1 >50
SYPL2 >50
LCE2A >50 ++
MOSC1 >50
TOMM40L >50
CDNA FLJ32320 fis >50
SDPR >50
PPFIA2 >50
KIAA1147 >50
C6orf138 >50 ++
DSCC1 >50
POLR3G >50
ETV4 >50
PARG >50
SIGLEC15 >50
Clone IMAGE:35527 >50
LEPR >50
RBM24 >50
BRI3BP >50
ANXA1 >50
HSFE-1 >50
Clone 23555 >50
CCIN >50
CACNA1H >50
SLC7A14 >50
KLRF1 >50 +
PANK1 >50 ++
ENPP5 >50
CPEB2 >50
C11orf41 >50
cDNA DKFZp686O 1044 >50
TFDP1 >50
RASD1 >50
NAP1L2 >50
DHRS12 >50
EIF2C1 >50
SLC7A14 >50
CLCA2 >50 ++
CYP3A5 >50
Table W1. (continued ).
Gene P26/P3 p53 Induction
RNLS >50
MAST4 41.74
SFRP4 41.67
RGS2 40.24
DTL 39.38
NPTX1 30.78
INA 29.34
NAT8L 28.66 +
MMP1 28.28
DBNDD1 24.25
CCND1 22.55
ATP8B4 22.11
GLTPD1 22.02
MET 21.58
CCND1 20.73
MFAP1 20.20
CCND2 18.71
C9orf57 18.21
FNDC5 16.78
PHLDA1 15.91
CIT 15.55
SLC1A2 15.32
KLHDC9 14.87
TOR1AIP1 14.55
IFIT2 14.42
ENY2 14.26
RNF219 13.97
CDNA: FLJ21245 fis 13.40 ++
PRKG2 12.32
TNIK 12.06
APBA1 11.76
TMEM158 11.58 +
E2F7 11.33 +
CNTN3 10.96
CYYR1 10.93
SLC35A3 10.77
GPR68 10.76
SYNM 10.63
ITGA6 10.56
VWF 10.54
PLCB1 10.38
CENPQ 10.19
“+” indicates more than 5-fold induction at 24 or 48 hours after infection with Ad-p53; “++,”
more than 10-fold induction at 24 or 48 hours after infection with Ad-p53.
Figure W2. Ectopic expression of p53 induced CLCA2 protein. (A)
Western blot analysis of CLCA2 protein in U373MG cells at 48 hours
after infection with Ad-p53 or Ad-LacZ at indicated doze. CBB
staining was used for the normalization protein loading. siCLCA2_1,
siCLCA2_2, or siEGFP was transfected at 7 hours before adenovirus
infection at 20MOI. Black arrowhead indicates CLCA2 protein; open
arrowhead, nonspecific band. (B) Quantitative RT-PCR analysis of
CLCA2 in U373MG cells 48 hours after infection with Ad-LacZ or
Ad-p53 at 20 MOI. siCLCA2_1, siCLCA2_2, or siEGFP was trans-
fected 7 hours before adenovirus infection.
Figure W3. Comparison of mouse Clca5 and human CLCA2. (A) Alignment of mouse p53BS and human p53BS. Nucleotides conserved
between human and mouse are written in capital letters. (B) Genomic structures of the mouse Clca5 and human CLCA2 genes. Gray
boxes indicate the locations and relative sizes of the two exons. Arrows indicate the locations of potential p53-binding sites. (C) Results
of luciferase assay of p53BR are shown. Luciferase activity is indicated relative to the activity of mock vector with SDs (n = 2).
Figure W4. Suppression of CLCA2 expression in colorectal cancer tissues. (A) Relative CLCA2 expressions in colorectal cancer tissues
compared with normal tissues were examined by quantitative real-time PCR analysis. β -Actin was used for the normalization of expres-
sion levels. (B) Seven colorectal cancer cell lines were treated with 1 or 5 μM of 5-Aza. CLCA2 expressions were examined by quanti-
tative real-time PCR analysis. β2-Microglobulin was used for the normalization of expression levels. (C) CLCA2 expressions were
examined by quantitative real-time PCR analysis. β2-Microglobulin was used for the normalization of expression levels. (D) CLCA2 ex-
pressions were examined by quantitative real-time PCR analysis in 21 colorectal cancer cell lines. β2-Microglobulin was used for the
normalization of expression levels. Student’s t test was applied for comparing the CLCA2 expressions in p53 mutant cell lines with those
in p53 wild-type cell lines.
Table W2. List of Cancer Cell Lines.
No. Colorectal Cancer Cell Lines
1 DLD-1
2 HCT-15
3 HT-29
4 KM12C
5 KM12SM
6 NCI-H508
7 NCI-H684
8 NCI-H716
9 SNU-C2A
10 SNU C5
11 SW480
12 SW620
13 SW948
14 WiDr
15 HCT 116
16 LoVo
17 LS 174T
18 NCI-H498
19 RKO
20 SNU C4
21 SW48
Table W3. Sequences of Primers and RNA Nucleotides.
Sense Antisense
siRNA oligonucleotides
siCLCA2_1 GGAAUUUACUCGAGGUAUUTT AAUACCUCGAGUAAAUUCCTT
siCLCA2_2 GAUGAAUGCUCCAAGGAAATT UUUCCUUGGAGCAUUCAUCTT
sip53 GACUCCAGUGGUAAUCUACTT GUAGAUUACCACUGGAGUCTT
siEGFP GCAGCACGACUUCUUCAAGTT CUUGAAGAAGUCGUGCUGCTT
Forward Reverse
Quantitative real-time PCR (SYBR Green I Master)
CLCA2 ATACCTGCCACATGGAAAGC CCTCTTTTCCACACCCTCTG
p21WAF1 AAGATCAGCCGGCGTTTG GACCTGTCACTGTCTTGTACCC
β2-Microglobulin TCTCTCTTTCTGGCCTGGAG AATGTCGGATGGATGAAACC
Clca5 (mouse) CCGAGTGGTCTGCTTAGTGA TACAGTTCGGCTGCTTGTTG
β-Actin (mouse) CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA
p16 AGCATGGAGCCTTCGGCTGA CCATCATCATGACCTGGATCG
Quantitative real-time PCR (Probe Master)
CLCA2 no. 21 AGAAGAGGTCAGCAGGGAGA CTCTTGATGGAGAAAGGATTAAAGA
β-Actin no. 55 TAGGAGGGCTGGCAACTTAG CCAAGATGTTGATGTTGGATAAGA
Site-directed mutagenesis
mClca5_mtp53BS1 AGATAGTTCCCAGATAGATCCACCCCA CTAAAAATTCCTCTCCAAGGCAACGC
mClca5_mtp53BS2 GAATGTTCTCAAGAGGTGTGACTTAA AGGACTATGCCTTTTAAAAACATTATT
mClca5_mtp53BS3 TAATATTTAATCAGTGTGCTAAAATCT GGGATTACGCTCATGATCTCCCCAAGT
Semiquantitative RT-PCR
CLCA2 CAGATGTGCAGCCTCAGAAG TGCTGAGCACAGTGGGTAAG
p21WAF1 GTTCCTTGTGGAGCCGGAGC GGTACAAGACAGTGACAGGTC
β2-Microglobulin CACCCCCACTGAAAAAGATGA TACCTGTGGAGCAACCTGC
